

Early and Locally Advanced Breast Cancer (update) Committee meeting 5

Date: 15/03/17

Location: RCOG, London

Minutes: Final

Committee members present:		
Jane Barrett	(Present for notes 1 – 8)	
Anne Armstrong	(Present for notes 1 – 8)	
Ramsey Cutress	(Present for notes 1 – 8)	
Linda Pepper	(Present for notes 1 – 8)	
Mia Rosenblatt	(Present for notes 4 – 8)	
Lisa Whisker	(Present for notes 1 – 8)	
Sairanne Wickers	(Present for notes 1 – 8)	
Roger Hunt	(Present for notes 1 – 8)	
Ursula Van Mann	(Present for notes 1 – 8)	
Peter Jenkins	(Present for notes 1 – 8)	
Faye Coe	(Present for notes 1 – 8)	
Imogen Locke	(Present for notes 1 – 8)	
Marina Parton	(Present for notes 1 – 8)	
Sadaf Haque	(Present for notes 1 – 8)	

In attendance:			
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 8)	
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1 – 8)	
Laura O'Shea	NGA Systematic Reviewer	(Present for notes 1 – 8)	
John Graham	NGA Clinical Advisor	(Present for notes 1 – 8)	
Anne Carty	NGA Project Manager	(Present for notes 1 – 8)	
Sarah Palombella	NICE Senior Editor	(Present for notes 1 – 8)	

Observers:	
None	



Apologies:		
Carmel Gulliver- Clarke	GC member	(Absent for notes 1 – 8)
William Teh	GC member	(Present for notes 1 – 8)
Clifford Middleton	NICE Guideline Commissioning Manager	(Absent for notes 1 – 8)
Matthew Prettyjohns	NGA Senior Health Economist	(Absent for notes 1 – 8)
Lianne Gwillim	NGA project manager	(Absent for notes 1-8)
Ferruccio Pelone	NGA Assistant Systematic Reviewer	(Absent for notes 1-8)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 5th meeting on Early and Locally Advanced Breast Cancer (update).

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting which included: reviewing the evidence and drafting recommendations for questions 8.2, 2.1 and 8.4

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Declarations of Interest, date declared	Type of interest	Decision taken
Lisa Whisker	Local investigator for the SENTIMAG trial (comparison of using magnetic tracer to identify the sentinel nodes with standard technique). Trial funded by Sysmex	Non- personal financial non- specific	Declare and participate. Sentinel nodes not being investigated by the guideline.
Lisa Whisker	Local lead investigator for the TissuGlu trial (RCT using Glu instead of a drain in closure of mastectomy wounds). Trial funded by Cohera	Non- personal financial, non- specific	Declare and participate. Techniques for wound closure are not being investigated by the guideline
Anne Armstrong	Attendance at Accelerating Cancer Immunotherapy conference in March 2017 was funded by the	Personal financial non-	Declare and participate



1	conference organisers (Oncology	specific	
	at the Limits). Organisers get		
	industry sponsorship to run the		
	event but industry has no input into		
	the programme. Content of		
	conference is about all		
	immunotherapy – no focus on		
	breast cancer.		

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Nathan Bromham, who gave a presentation on the evidence for question 8.2. Nathan took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced Nathan Bromham, who gave a presentation on the evidence for question 2.1. Nathan took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced Sarah Palombella, who gave a presentation on the role of the NICE Editor. Sarah took questions from the group.

The Chair introduced Nathan Bromham, who gave a presentation on the evidence for question 8.4. Nathan took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

5. Questions and discussion

The Committee discussed the evidence for questions 8.2, 2.1 and 8.4 and agreed recommendations and content for the LETR.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 5th May 2017



Location of next meeting: RCOG, London